Lipodissolve ultrasound studies reveal no migration to adjacent tissue occur from injections

MELK, Austria (July 2005): In effort to support and verify Lipodissolve safety reports from contributing Members data, study groups are encouraged to be undertaken by Members. Study groups conduct individual Lipodissolve studies according to each group's field of speciality. ASAL focus on studies for Lipodissolve use within plastic surgery, while the European groups pay emphasiz on Lipodissolve in general clinical use.

One of the new study groups in Europe have turned their focus on ultrasonic imaging. Under the leadership of OB-Gyn physician Dr. Wojciech Norek, Austria, Lipodissolve studies supported by the latest technologies in Ultrasound has been undertaken in Austria since the early part of 2005. Dr Norek's new ultrasound studies focus to report detailed image data on the before and after effect of Lipodissolve injections. The concept whether fat reducing injections would migrate has been a topic of curiosity and safety concerns within the medical community. One concern expressed by the American Society of Aesthetic Plastic Surgeons (ASAPS) with latest fat reducing injections (mesotherapy, lipodissolve) include the question of migration: "If fatty tissue is being dissolved, is other adjacent tissue also affected? How is delivery limited to only the target tissues?".

Dr Norek's new studies from ultrasonic imaging reveal that the injections, - according to the Lipodissolve protocol of 4 standardized medications - has no adverse effect on adjacent tissue but remain nestled within the fat in the size of a table-tennis ball.

Immediately after Lipodissolve injections: the spread of the pharmaceutical agents spread to the size of a table-tennis ball.

After 4 weeks: The medications stay netted in the tissue without migration.

After 6 weeks: The lipolysis process is still active in the 6th week

After 8 weeks: the lipolysis process reach completion in the 8th week

The study group, lead by Dr Norek, developed custom features to the software for ultrasound documentation specific for Lipodissolve injections. The latest cutting edge ultrasound technology, AccuVix QX live imagry, is being used to evaluate Lipodissolve injection in relation to distribution, injection depth, time frame for the lipolysis process, and whether any signs of necrosis result from Lipodissolve treatments.

The state-of-the-art AccuVix QX ultrasound scanner is the newest and most advanced model in the medical field and has become popular for live color 3D imaging of foetal development. AccuVix is able to capture extreme detailed and accurate images in 2D, 3D and 4D format.

Dr Norek's study group is currently developing a method that aims to measure the thickness of the fat layer with absolute precision. The study efforts aim to give a more accurate understanding of the medical effect of Lipodissolve on fat and adjacent tissue.

(Right) Dr Wojciech Norek, OB-Gyn, inspect latest ultrasound technology to measure Lipodissolve effect on the fat layer and adjacent tissue.